Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
24 Agosto 2023 - 9:00AM
Business Wire
HQ pDNA will be used to produce GMP lentivirus
for ex vivo gene therapy
Charles River Laboratories International, Inc. (NYSE: CRL),
today announced a High Quality (HQ) plasmid manufacturing
collaboration with Fondazione Telethon. The rare disease
organization will leverage Charles River’s market leading cell and
gene contract development and manufacturing organization (CDMO)
expertise in High Quality (HQ) plasmid DNA production, and Good
Manufacturing Practice- (GMP) compliant plasmid DNA batches to
manufacture HQ plasmid DNA for Fondazione Telethon’s lentivirus
production that will be used in ex vivo cell and gene therapy.
Fondazione Telethon is a non-profit organization and an
internationally recognized biomedical research foundation focused
on advancing biomedical research to cure rare genetic diseases.
Founded in 1990, the Fondazione Telethon supports and finances
scientific research of excellence for the study and treatment of
genetic diseases. These efforts focus on developing effective
therapies against these serious pathologies.
A Robust Manufacturing Collaboration
Through this collaboration, Fondazione Telethon will have access
to established manufacturing platforms and multiple Charles River
CDMO centers of excellence, leveraging a comprehensive range of
services including, but not limited to, GMP cell banking and HQ and
GMP-grade plasmid DNA manufacturing.
Plasmid DNA Manufacturing Services
Charles River’s plasmid DNA production, specifically HQ plasmid
production, combines key features of GMP manufacturing leading to
rapid turnaround times and accelerated clinical application.
Plasmid DNA is a critical starting material for many cell and gene
therapies with a demand that continues to outstrip supply. In
response, Charles River recently announced the opening of a
state-of-the-art HQ plasmid manufacturing center of excellence to
address the supply shortages and support the growing needs of the
cell and gene therapy field.
Approved Quotes
- “We are thrilled to work with Fondazione Telethon to produce HQ
plasmid DNA for Fondazione Telethon’s lentivirus for ex vivo gene
therapy. Charles River has had decades of success developing,
producing, and reliably delivering plasmid DNA, which provides
confidence customers are in safe hands.” - Kerstin Dolph, Corporate
Senior Vice President, Biologics Solutions, Charles River
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230824143148/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com
Charles River Media Contact: Amy Cianciaruso Corporate
Vice President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024